Impedimed Ltd (ASX:IPD)
A$ 0.053 0 (0%) Market Cap: 107.22 Mil Enterprise Value: 83.73 Mil PE Ratio: 0 PB Ratio: 2.65 GF Score: 0/100

Q1 2023 ImpediMed Ltd Activities Report Call Transcript

Oct 19, 2022 / 05:30AM GMT
Release Date Price: A$0.069 (+1.47%)
Operator

Thank you for standing by, and welcome to the ImpediMed Limited quarterly results conference call. (Operator Instructions) I would now like to hand the conference over to Mr. Mike Bassett. Please go ahead.

Michael John Bassett
ImpediMed Limited - Senior VP of Corporate & Strategic Development and GM of Renal

Thank you, Sari. Welcome, everyone, and thank you for joining us today. We're hosting this conference call to discuss our 4C for the financial quarter ending 30 September 2022. I'm Mike Bassett, Senior Vice President of Corporate and Strategic Development. Joining us today on the call is Dave Anderson, Interim CEO; and Tim Cruickshank, our Chief Financial Officer. We'll be referring to 4C and speaking from the quarterly activity report we launched this afternoon, Australia time with the ASX. This presentation is a summary of a more detailed 4C. After our remarks, we'll be taking questions.

Before I turn over to Dave, I'd first like to bring your attention to the record that disclaimer on Page 2 of the presentation deck, the presentation deck

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot